115 results on '"Hooper WD"'
Search Results
2. Studies on the renal excretion of the acyl glucuronide, phenolic glucuronide and sulphate conjugates of diflunisal.
- Author
-
Dickinson, RG, primary, King, AR, additional, McKinnon, GE, additional, Hooper, WD, additional, Eadie, MJ, additional, and Herkes, GK, additional
- Published
- 1993
- Full Text
- View/download PDF
3. Lack of a pharmacokinetic interaction between phenobarbitone and gabapentin.
- Author
-
Hooper, WD, primary, Kavanagh, MC, additional, Herkes, GK, additional, and Eadie, MJ, additional
- Published
- 1991
- Full Text
- View/download PDF
4. The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin.
- Author
-
Dickinson, RG, Hooper, WD, Wood, B, Lander, CM, and Eadie, MJ
- Abstract
1. To investigate the mechanism of the fall in steady-state plasma phenytoin concentration relative to drug dose that occurs during pregnancy, single dose pharmacokinetic studies with stable isotope labelled phenytoin were carried out at different stages of pregnancy, and 2 to 4 months post-natally, in five epileptic women receiving regular oral therapy with the drug. 2. Steady-state apparent plasma clearances of phenytoin (dose/steady-state concentration) correlated closely with simultaneous plasma clearances of the intravenous stable- isotope drug (measured as dose/AUC) suggesting that the patients were complaint with therapy when their phenytoin dosage requirement increased during the pregnancy, and that the oral drug was fully bioavailable. 3. In retrospect, two of the five subjects were probably studied too early post-natally for phenytoin elimination kinetics to have returned to non-pregnant values. Despite this, (i) the mean +/- s.d. t 1/2 for phenytoin was statistically significantly shorter in pregnancy than post-natally (31 +/- 14 vs 39 +/- 28 h), (ii) the mean +/- s.d. whole plasma clearance was also statistically significant greater (0.025 +/- 0.012 vs 0.021 +/- 0.013 kg-1 h-1) and (iii) the mean +/- s.d. Vmax for phenytoin elimination was statistically significantly greater in pregnancy (1170 +/- 600 mg day-1) than post- natally (780 +/- 470 mg day-1). Although the mean +/- s.d. apparent Km was higher in pregnancy (18.2 +/- 8.4 mg l-1, expressed in terms of whole plasma drug concentrations, compared with 10.2 +/- 7.4 mg l-1 post-natally), the difference was not statistically significant. However, if the apparent Km value was expressed in terms of plasma water phenytoin concentrations the difference (pregnant 2.50 +/- 0.85 mg l-1: post-natally 1.16 +/- 0.65 mg l-1) was statistically significant. 4. Human pregnancy appears to result in an increased capacity to eliminate phenytoin. [ABSTRACT FROM AUTHOR]
- Published
- 1989
- Full Text
- View/download PDF
5. Disopyramide pharmacokinetics and bioavailability.
- Author
-
Dubetz, DK, primary, Brown, NN, additional, Hooper, WD, additional, Eadie, MJ, additional, and Tyrer, JH, additional
- Published
- 1978
- Full Text
- View/download PDF
6. Factors influencing plasma phenobarbitone levels in epileptic patients.
- Author
-
Eadie, MJ, primary, Lander, CM, additional, Hooper, WD, additional, and Tyrer, JH, additional
- Published
- 1977
- Full Text
- View/download PDF
7. Disposition of naproxen, naproxen acyl glucuronide and its rearrangement isomers in the isolated perfused rat liver.
- Author
-
Lo A, Addison RS, Hooper WD, and Dickinson RG
- Subjects
- Acylation, Animals, Bile metabolism, Half-Life, Hydrolysis, Isomerism, Kinetics, Male, Rats, Rats, Sprague-Dawley, Anti-Inflammatory Agents, Non-Steroidal metabolism, Glucuronides metabolism, Liver metabolism, Naproxen metabolism
- Abstract
1. An isolated perfused rat liver (IPRL) preparation was used to investigate separately the disposition of the non-steroidal anti-inflammatory drug (NSAID) naproxen (NAP), its reactive acyl glucuronide metabolite (NAG) and a mixture of NAG rearrangement isomers (isoNAG), each at 30 microg NAP equivalents ml perfusate (n = 4 each group). 2. Following administration to the IPRL, NAP was eliminated slowly in a log-linear manner with an apparent elimination half-life (t 1/2) of 13.4 +/- 4.4h. No metabolites were detected in perfusate, while NAG was the only metablolite present in bile in measurable amounts (3.9 +/- 0.8% of the dose). Following their administration to the IPRL, both NAG and isoNAG were rapidly hydrolysed (t 1/2 in perfusate = 57 +/- 3 and 75 +/- 14 min respectively). NAG also rearranged to isoNAG in the perfusate. Both NAG and isoNAG were excreted intact in bile (24.6 and 14.8% of the NAG and isoNAG doses, respectively). 3. Covalent NAP-protein adducts in the liver increased as the dose changed from NAP to NAG to isoNAG (0.20 to 0.34 to 0.48% of the doses, respectively). Similarly, formation of covalent NAP-protein adducts in perfusate were greater in isoNAG-dosed perfusions. The comparative results suggest that isoNAG is a better substrate for adduct formation with liver proteins than NAG.
- Published
- 2001
- Full Text
- View/download PDF
8. Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males.
- Author
-
Hooper WD, Eadie MJ, Blakey GE, Lockton JA, and Manun'Ebo M
- Subjects
- Acetamides administration & dosage, Acetamides blood, Adult, Anticonvulsants administration & dosage, Anticonvulsants blood, Anticonvulsants pharmacokinetics, Area Under Curve, Drug Interactions, Humans, Male, Metabolic Clearance Rate, Phenobarbital administration & dosage, Acetamides pharmacokinetics, Phenobarbital pharmacology
- Abstract
Aims: To determine whether there is a pharmacokinetic interaction between the antiepileptic drugs remacemide and phenobarbitone., Methods: In a group of 12 healthy adult male volunteers, the single dose and steady-state kinetics of remacemide were each determined twice, once in the absence and once in the presence of phenobarbitone. The effect of 7 days remacemide intake on initial steady-state plasma phenobarbitone concentrations was also investigated., Results: Apparent remacemide clearance (CL/F) and elimination half-life values were unchanged after 7 days intake of the drug in the absence of phenobarbitone (1.25 +/- 0.32 vs 1.18 +/- 0.22 l kg(-1) h(-1) and 3.29 +/- 0.68 vs 3.62 +/- 0.85 h, respectively). Concomitant administration of remacemide with phenobarbitone resulted in an increase in the estimated CL/F of remacemide (1.25 +/- 0.32 vs 2.09 +/-0.53 l kg-1 h-1), and a decreased remacemide half-life (3.29 +/- 0.68 vs 2.69 +/- 0.33 h). The elimination of the desglycinyl metabolite of remacemide also appeared to be increased after the phenobarbitone intake (half-life 14.72 +/- 2.82 vs 9.61 +/- 5.51 h, AUC 1532 +/- 258 vs 533 +/- 281 ng ml(-1) h). Mean plasma phenobarbitone concentrations rose after 7 days of continuing remacemide intake (12.67 +/- 1.31 vs 13.86 +/- 1.81 microgram ml(-1))., Conclusions: Phenobarbitone induced the metabolism of remacemide and that of its desglycinyl metabolite. Remacemide did not induce its own metabolism, but had a modest inhibitory effect on the clearance of phenobarbitone.
- Published
- 2001
- Full Text
- View/download PDF
9. Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults.
- Author
-
Reith DM, Hooper WD, Parke J, and Charles B
- Subjects
- Adolescent, Adult, Age Factors, Anticonvulsants blood, Biological Availability, Body Height physiology, Body Surface Area, Body Weight physiology, Carbamazepine blood, Child, Child, Preschool, Drug Interactions, Drug Monitoring, Female, Humans, Individuality, Infant, Male, Sex Factors, Anticonvulsants pharmacokinetics, Carbamazepine pharmacokinetics, Models, Biological
- Abstract
Carbamazepine (CBZ) clearance decreases from childhood to adulthood and the factors determining this change could include age, size, autoinduction, or maturational changes. This study aims to describe the population pharmacokinetics of CBZ in children and young adults and test the hypothesis that CBZ clearance correlates with weight, surface area, and age. CBZ therapeutic drug monitoring data (sparse data) were collected from child and adult epileptics, and rich data were obtained from a bioequivalence study of CBZ in young adults. Population pharmaco-kinetic analysis was performed using NONMEM V. Forward stepwise, multiple regression was performed on the covariates. Bootstrap validation was performed. A total of 946 observations from 91 subjects, ages 0.7-37 years, were collected and analyzed. A one-compartment, first-order absorption and elimination model, with exponential interindividual error and additive residual error models was developed. The population model was: Clearance (Lhr-1) = ((2.24 x Surface area (m2)) + (0.047 x Dose (mg.kg-1)); Volume of distribution (L) = 0.37 x weight (kg); Absorption rate constant = 0.013 (hr-1). CBZ clearance increased with surface area and dose.
- Published
- 2001
- Full Text
- View/download PDF
10. Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers.
- Author
-
Addison RS, Parker-Scott SL, Eadie MJ, Hooper WD, and Dickinson RG
- Subjects
- Adult, Area Under Curve, Biotransformation, Drug Interactions, Glucuronides metabolism, Half-Life, Humans, Male, Oxidation-Reduction, Anti-Inflammatory Agents, Non-Steroidal pharmacokinetics, Anticonvulsants pharmacokinetics, Diflunisal pharmacokinetics, Valproic Acid pharmacokinetics
- Abstract
Objective: The effects of coadministration of the non-steroidal anti-inflammatory drug diflunisal (DF) on glucuronidation and beta-oxidation of the antiepileptic agent valproic acid (VPA), and of VPA on DF glucuronidation, were studied in human volunteers., Methods: Seven healthy male volunteers received sodium valproate (NaVPA, 200 mg) orally twice daily for 7 days, after which all drug intake ceased for 1 month. The volunteers then took DF (250 mg) orally twice daily for 7 days. Both drugs were then taken (at the same doses as previously) twice daily for 7 days. On day 7 of each dosing phase, serial blood samples and all urine passed over the 12-h inter-dosing interval were collected. VPA, DF and selected metabolites were analysed using validated methods. Statistical comparisons of pharmacokinetic parameters were made using paired Student's t-tests., Results: Mean plasma concentrations of total VPA were lower and apparent plasma clearances significantly higher during DF coadministration. This was associated with a significant 20% increase in the unbound fraction of VPA (from 6.6+/-1.3% to 7.9+/-1.8%). The apparent clearance of unbound VPA was not different. There was no evidence of any significant effect of DF coadministration on VPA metabolism: urinary recoveries of and formation clearances to urinary VPA-glucuronide, E-2-en-VPA, 3-oxo-VPA and 4-en-VPA were not significantly altered. However, there was a highly significant 35% increase in the area under the plasma concentration-time curve from 0-12 h (AUC0-12h) of 3-oxo-VPA and its renal clearance was lower, though not significantly so. VPA coadministration had no effect on DF pharmacokinetics or formation clearances of DF to its acyl glucuronide (DAG), phenolic glucuronide (DPG) or sulfate (DS) conjugates. However, plasma AUC0-12h values of the glucuronides were significantly lower and their renal clearances higher (though significantly so only in the case of DPG) during VPA coadministration., Conclusions: Steady-state coadministration of VPA and DF leads to a significant displacement of VPA from plasma protein binding sites. There was no evidence of competition for glucuronidation capacity or other metabolic interactions. Rather, the interactions detected appeared to be renal in nature, with renal clearance of 3-oxo-VPA being reduced by DF coadministration, and renal clearance of DPG and perhaps DAG being increased by VPA coadministration.
- Published
- 2000
- Full Text
- View/download PDF
11. Valproate metabolism during valproate-associated hepatotoxicity in a surviving adult patient.
- Author
-
McLaughlin DB, Eadie MJ, Parker-Scott SL, Addison RS, Henderson RD, Hooper WD, and Dickinson RG
- Subjects
- Adult, Biotransformation, Electroencephalography, Epilepsies, Partial complications, Epilepsies, Partial drug therapy, Humans, Liver Function Tests, Male, Tomography, X-Ray Computed, Anticonvulsants adverse effects, Anticonvulsants pharmacokinetics, Chemical and Drug Induced Liver Injury metabolism, Valproic Acid adverse effects, Valproic Acid pharmacokinetics
- Abstract
The plasma profiles of valproate (VPA), its beta-oxidation metabolites E-2-en-VPA and 3-oxo-VPA and its terminal desaturation metabolite 4-en-VPA, have been measured in a patient receiving NaVPA 1000 mg twice per day from early in the course of serious hepatotoxicity and for 2 weeks after the drug was stopped. Concurrent profiles of liver, renal and haematological function parameters were available. Relative to concurrent plasma VPA concentrations, E-2-en-VPA concentrations were not different to those of the VPA-treated epileptic population at any stage of the illness, whereas 3-oxo-VPA concentrations relative to concurrent VPA concentrations were abnormally high early in the toxicity, abnormally low at its peak (3-5 days later), and comfortably within normal limits for the treated epileptic population late in the recovery phase (9-13 days from the onset). When measurable, plasma 4-en-VPA concentrations were not elevated. The elimination half-life of VPA during the recovery phase was 100 h, which is some 6-12 times greater than values reported for this parameter in normal patients. These data clearly define, in this patient, a link between idiosyncratic VPA-associated hepatotoxicity at its onset and peak and the later stages of VPA beta-oxidation. Whether the beta-oxidation abnormalities are causative or a consequence of an as yet undefined defect is unknown. In this patient, 4-en-VPA was unlikely to have been involved in the pathogenesis of the toxicity.
- Published
- 2000
- Full Text
- View/download PDF
12. Effect of naproxen co-administration on valproate disposition.
- Author
-
Addison RS, Parker-Scott SL, Hooper WD, Eadie MJ, and Dickinson RG
- Subjects
- Adult, Area Under Curve, Biotransformation, Drug Interactions, Gas Chromatography-Mass Spectrometry, Glucuronides metabolism, Humans, Male, Middle Aged, Oxidation-Reduction, Spectrophotometry, Ultraviolet, Anti-Inflammatory Agents, Non-Steroidal pharmacokinetics, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Anticonvulsants pharmacokinetics, Anticonvulsants pharmacology, Naproxen pharmacokinetics, Naproxen pharmacology, Valproic Acid pharmacokinetics, Valproic Acid pharmacology
- Abstract
The effects of co-administration of the antiepileptic agent valproic acid (VPA) and the non-steroidal anti-inflammatory drug naproxen (NAP) on their relative dispositions (particularly with respect to glucuronidation) were investigated in human volunteers. Seven healthy males received each drug alone and then in combination (orally twice daily for seven days, 500 mg sodium VPA, 500 mg NAP). On day 7 of each dosing phase, serial plasma and 24 h urine samples were collected for analysis. Co-administration of NAP resulted in significant increases (about 20%, p<0.05) in the apparent plasma clearance of total VPA and in the unbound fraction of VPA in plasma, with the apparent plasma clearance of unbound VPA being unchanged. There were associated increases in the formation clearances to urinary VPA-glucuronide and 3-oxo-VPA, though these were relatively greater for the glucuronidation pathway (and remained significant when formation clearances were calculated using the unbound fraction of drug in plasma). The data thus point to a shift towards glucuronidation as a result of the NAP-induced increase in the unbound fraction of VPA in plasma. By contrast, VPA co-administration caused a decrease (of about 10%, p<0.05) in the apparent plasma clearance of total NAP. Taken in hand with in vitro results showing a VPA-induced displacement (of about 40%) of NAP from plasma protein binding sites, the data strongly support a role for diminished glucuronidation of NAP and its desmethyl metabolite in the presence of co-administered VPA., (Copyright 2000 John Wiley & Sons, Ltd.)
- Published
- 2000
- Full Text
- View/download PDF
13. Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation.
- Author
-
Cuttle L, Munns AJ, Hogg NA, Scott JR, Hooper WD, Dickinson RG, and Gillam EM
- Subjects
- Autoimmunity, Catechols analysis, Cytochrome P-450 CYP3A, Cytochrome P-450 Enzyme System immunology, Epitopes immunology, Humans, Oxidoreductases, N-Demethylating immunology, Recombinant Proteins metabolism, Anticonvulsants metabolism, Aryl Hydrocarbon Hydroxylases, Cytochrome P-450 Enzyme System metabolism, Oxidoreductases, N-Demethylating metabolism, Phenytoin metabolism
- Abstract
The anticonvulsant phenytoin (5,5-diphenylhydantoin) provokes a skin rash in 5 to 10% of patients, which heralds the start of an idiosyncratic reaction that may result from covalent modification of normal self proteins by reactive drug metabolites. Phenytoin is metabolized by cytochrome P450 (P450) enzymes primarily to 5-(p-hydroxyphenyl-),5-phenylhydantoin (HPPH), which may be further metabolized to a catechol that spontaneously oxidizes to semiquinone and quinone species that covalently modify proteins. The aim of this study was to determine which P450s catalyze HPPH metabolism to the catechol, proposed to be the final enzymatic step in phenytoin bioactivation. Recombinant human P450s were coexpressed with NADPH-cytochrome P450 reductase in Escherichia coli. Novel bicistronic expression vectors were constructed for P450 2C19 and the three major variants of P450 2C9, i.e., 2C9*1, 2C9*2, and 2C9*3. HPPH metabolism and covalent adduct formation were assessed in parallel. P450 2C19 was the most effective catalyst of HPPH oxidation to the catechol metabolite and was also associated with the highest levels of covalent adduct formation. P450 3A4, 3A5, 3A7, 2C9*1, and 2C9*2 also catalyzed bioactivation of HPPH, but to a lesser extent. Fluorographic analysis showed that the major targets of adduct formation in bacterial membranes were the catalytic P450 forms, as suggested from experiments with human liver microsomes. These results suggest that P450 2C19 and other forms from the 2C and 3A subfamilies may be targets as well as catalysts of drug-protein adduct formation from phenytoin.
- Published
- 2000
14. Apparent autoinduction of valproate beta-oxidation in humans.
- Author
-
McLaughlin DB, Andrews JA, Hooper WD, Cannell GR, Eadie MJ, and Dickinson RG
- Subjects
- Adolescent, Adult, Female, Humans, Male, Metabolic Clearance Rate, Oxidation-Reduction, Anticonvulsants pharmacokinetics, Valproic Acid pharmacokinetics
- Abstract
Aims: The study aimed to show whether autoinduction of valproate (VPA) along its beta-oxidation pathway occurred upon chronic dosing in humans., Methods: Twelve young volunteers without active illness took sodium valproate (NaVPA) 200 mg orally 12 hourly for 3 weeks. On days 7 and 21, serial blood samples and all urine passed over an interdosing interval from 08.00 to 20.00 h were collected for analysis of VPA and certain metabolites., Results: Plasma AUC(0,12 h) of VPA was significantly lower on day 21 than on day 7 (2.40 vs 2.84 micromol ml-1 h, 95% CI for the difference 0.13-0.81 micromol ml-1 h). Significant differences in plasma AUC(0,12 h) of the beta-oxidation metabolites E-2-en-VPA and 3-oxo-VPA were not found. However, formation clearances of plasma VPA to urinary E-2-en-VPA and 3-oxo-VPA were significantly increased from day 7 to day 21 (0. 010 vs 0.024 and 2.57 vs 3.60 ml kg-1 h-1, respectively, 95% CI for the differences -0.025 to -0.004 and -1.72 to -0.34 ml kg-1 h-1, respectively). Formation clearances to VPA-glucuronide (0.534 vs 0. 505 ml kg-1 h-1) and 4-OH-VPA (0.112 vs 0.110 ml kg-1 h-1) were not significantly different., Conclusions: Regular low dose VPA intake in humans over a period of 3 weeks appears to be associated with a small induction of its metabolism by the beta-oxidation pathway, but not by glucuronidation or 4-hydroxylation.
- Published
- 2000
- Full Text
- View/download PDF
15. The effect of diflunisal on the elimination of triamterene in human volunteers.
- Author
-
Jacob SS, Franklin ME, Dickinson RG, and Hooper WD
- Subjects
- Adult, Chromatography, High Pressure Liquid methods, Diuretics blood, Diuretics urine, Drug Interactions, Female, Humans, Male, Middle Aged, Triamterene blood, Triamterene urine, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Cyclooxygenase Inhibitors pharmacology, Diflunisal pharmacology, Diuretics pharmacokinetics, Triamterene pharmacokinetics
- Abstract
A major metabolic pathway for triamterene (a potassium sparing diuretic) is aromatic hydroxylation followed by sulphate conjugation. Diflunisal (a salicylate anti-inflammatory agent) also undergoes sulphate conjugation of its phenolic group as a major pathway. We investigated the possible effect of diflunisal on the elimination of triamterene (competition for phenolic sulphonation) in six healthy volunteers by studying the disposition of single doses of triamterene (100 mg) taken alone and in the presence of steady-state levels of diflunisal. Diflunisal coadministration (500 mg b.i.d.) had no effect on the pharmacokinetics of triamterene itself. However, plasma AUC of p-hydroxytriamterene sulphate was greater (4.6 times), and its renal clearance lower (0.24 times), in the presence of diflunisal. There was no change in the formation clearance or protein binding of p-hydroxytriamterene sulphate in the presence of diflunisal. The data point to competition for renal excretory pathways rather than sulphonation capacity. This interaction could have clinical relevance since p-hydroxytriamterene sulphate is pharmacologically active.
- Published
- 2000
- Full Text
- View/download PDF
16. Sensitive, high-throughput gas chromatographic-mass spectrometric assay for fluoxetine and norfluoxetine in human plasma and its application to pharmacokinetic studies.
- Author
-
Addison RS, Franklin ME, and Hooper WD
- Subjects
- Adult, Antidepressive Agents, Second-Generation, Humans, Sensitivity and Specificity, Fluoxetine analogs & derivatives, Fluoxetine blood, Fluoxetine pharmacokinetics, Gas Chromatography-Mass Spectrometry methods, Selective Serotonin Reuptake Inhibitors
- Abstract
A sensitive, robust gas chromatographic-mass spectrometric assay suitable for use in pharmacokinetic or bioequivalence studies is presented for the selective serotonin reuptake inhibitor, fluoxetine, and its major metabolite, norfluoxetine (N-desmethylfluoxetine). This method employs solid-phase extraction followed by acetylation with trifluoroacetic anhydride and analysis of the derivatives using selected ion monitoring. The lower limit of quantification was 1.0 ng/ml, and the assay was linear for both analytes from 1 to 100 ng/ml. Mean recoveries following solid-phase extraction at concentrations of 5.0, 20 and 100 ng/ml were 91% (fluoxetine) and 87% (norfluoxetine). Assay precision (as mean RSD) and accuracy (as mean relative error) for both analytes were tested at the same three nominal concentrations and were found to be within 10% in all cases. Analysis of fluoxetine concentrations in plasma samples from 18 volunteers following administration of a single 40 mg dose of fluoxetine provided the following pharmacokinetic data (mean+/-SD): Cmax, 32.73+/-9.21 ng/ml; AUC0-infinity, 1627+/-1372 ng/ml h; Tmax, 3.08 h (median); ke, 0.022+/-0.007 h(-1); elimination half-life, 37.69+/-21.70 h.
- Published
- 1998
- Full Text
- View/download PDF
17. Improved analytical procedure for the measurement of captopril in human plasma by gas chromatography--mass spectrometry and its application to pharmacokinetic studies.
- Author
-
Franklin ME, Addison RS, Baker PV, and Hooper WD
- Subjects
- Administration, Oral, Adult, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Angiotensin-Converting Enzyme Inhibitors pharmacokinetics, Captopril administration & dosage, Captopril pharmacokinetics, Gas Chromatography-Mass Spectrometry, Humans, Reproducibility of Results, Sensitivity and Specificity, Angiotensin I metabolism, Angiotensin-Converting Enzyme Inhibitors blood, Captopril blood
- Abstract
An enhanced, sensitive GC-MS assay is presented for the highly specific angiotensin-converting enzyme (ACE) inhibitor, captopril. This method improves previously published assays by using solid NEM as stabilizer in the collection tubes, a rapid extraction technique with dichloromethane and back-extraction into base, a commercially available internal standard (thiosalicylic acid) and a capillary GC column. Captopril and the internal standard are measured as their bis-pentafluorobenzyl derivatives. The assay was linear from 10 to 5000 ng/ml with a mean recovery following solvent extraction at 50, 200 and 1000 ng/ml of 77%. At mean values of 45.9, 187 and 980 ng/ml inter-assay precision and accuracy were 4.0, 2.9 and 3.5% and 8.2, 6.5 and 3.1%, respectively. Analysis of captopril concentrations in plasma samples from 20 volunteers following oral administration of 100 mg of captopril provided the following pharmacokinetic data (mean+/-S.D.): Cmax, 1470+/-467 ng/ml; AUC(0-infinity), 1736+/-481 ng/ml.h; Tmax, 0.73 h; k(e), 0.468+/-0.122 h(-1); elimination half life, 1.58/-0.41 h.
- Published
- 1998
- Full Text
- View/download PDF
18. Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation.
- Author
-
Munns AJ, De Voss JJ, Hooper WD, Dickinson RG, and Gillam EM
- Subjects
- Animals, Biotransformation physiology, Blotting, Northern, Cats, Chlorophyll analogs & derivatives, Chlorophyll metabolism, Chromatography, High Pressure Liquid, Electrophoresis, Polyacrylamide Gel, Female, Humans, In Vitro Techniques, Male, Microsomes, Liver metabolism, Molecular Weight, Photosensitizing Agents metabolism, Protein Binding, Rats, Rats, Wistar, Reactive Oxygen Species, Spectrometry, Fluorescence, Cytochrome P-450 Enzyme System metabolism, Phenytoin metabolism
- Abstract
The cytochrome P450-dependent covalent binding of radiolabel derived from phenytoin (DPH) and its phenol and catechol metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin (HPPH) and 5-(3',4'-dihydroxyphenyl)-5-phenylhydantoin (CAT), was examined in liver microsomes. Radiolabeled HPPH and CAT and unlabeled CAT were obtained from microsomal incubations and isolated by preparative HPLC. NADPH-dependent covalent binding was demonstrated in incubations of human liver microsomes with HPPH. When CAT was used as substrate, covalent adduct formation was independent of NADPH, was enhanced in the presence of systems generating reactive oxygen species, and was diminished under anaerobic conditions or in the presence of cytoprotective reducing agents. Fluorographic analysis showed that radiolabel derived from DPH and HPPH was selectively associated with proteins migrating with approximate relative molecular weights of 57-59 kDa and at the dye front (molecular weights < 23 kDa) on denaturing gels. Lower levels of radiolabel were distributed throughout the molecular weight range. In contrast, little selectivity was seen in covalent adducts formed from CAT. HPPH was shown to be a mechanism-based inactivator of P450, supporting the contention that a cytochrome P450 is one target of covalent binding. These results suggest that covalent binding of radiolabel derived from DPH in rat and human liver microsomes occurs via initial P450-dependent catechol formation followed by spontaneous oxidation to quinone and semiquinone derivatives that ultimately react with microsomal protein. Targets for covalent binding may include P450s, though the catechol appears to be sufficiently stable to migrate out of the P450 active site to form adducts with other proteins. In conclusion, we have demonstrated that DPH can be bioactivated in human liver to metabolites capable of covalently binding to proteins. The relationship of adduct formation to DPH-induced hypersensitivity reactions remains to be clarified.
- Published
- 1997
- Full Text
- View/download PDF
19. The mechanism of the carbamazepine-valproate interaction in humans.
- Author
-
Bernus I, Dickinson RG, Hooper WD, and Eadie MJ
- Subjects
- Adult, Anticonvulsants administration & dosage, Anticonvulsants therapeutic use, Carbamazepine administration & dosage, Carbamazepine analogs & derivatives, Carbamazepine blood, Carbamazepine therapeutic use, Carbamazepine urine, Drug Therapy, Combination, Epilepsy blood, Epilepsy drug therapy, Epilepsy urine, Female, Humans, Male, Middle Aged, Valproic Acid administration & dosage, Valproic Acid therapeutic use, Anticonvulsants pharmacokinetics, Anticonvulsants pharmacology, Carbamazepine pharmacokinetics, Epilepsy metabolism, Valproic Acid pharmacology
- Abstract
Aims: The study investigated the mechanism of the interaction between valproate and carbamazepine which causes raised plasma carbamazepine-10,11-epoxide concentrations with unchanged plasma carbamazepine concentrations. This interaction has usually been attributed to valproate inhibiting epoxide hydrolase, the enzyme that catalyses the biotransformation of carbamazepine-10,11-epoxide to carbamazepine-10,11-trans-diol., Methods: Clearances of plasma carbamazepine, carbamazepine-epoxide and carbamazepine-diol to relevant carbamazepine metabolites present in urine were measured under steady-state conditions in 17 adults receiving carbamazepine as anticonvulsant monotherapy, and in 10 adults taking the drug together with valproate., Results: Plasma carbamazepine-epoxide concentrations were higher, relative to carbamazepine dose, in the co-medicated patients. Plasma apparent clearances of carbamazepine, relative to drug dose, were similar whether or not valproate was taken. Formation clearances of carbamazepine-10,11-trans-diol conjugate, and probably of carbamazepine-10,11-trans-diol, were lower in subjects co-medicated with valproate, and a higher proportion of the carbamazepine dose was excreted in urine as carbamazepine-10,11-epoxide., Conclusions: Valproate appears to inhibit the glucuronidation of carbamazepine-10,11-trans-diol, and probably also inhibits the conversion of carbamazepine-10,11-epoxide to this trans-diol derivative, rather than simply inhibiting the latter reaction only.
- Published
- 1997
- Full Text
- View/download PDF
20. Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations.
- Author
-
Bernus I, Dickinson RG, Hooper WD, and Eadie MJ
- Subjects
- Absorption, Adult, Aged, Aged, 80 and over, Aging pathology, Aging physiology, Anticonvulsants administration & dosage, Anticonvulsants pharmacology, Biological Availability, Clinical Trials as Topic, Dose-Response Relationship, Drug, Female, Humans, Kidney drug effects, Liver drug effects, Male, Middle Aged, Sex Factors, Structure-Activity Relationship, Tissue Distribution, Aging metabolism, Anticonvulsants pharmacokinetics
- Abstract
Alterations in drug disposition that occur with aging are now becoming widely recognised, and there is an increasing number of drugs for which the approach to therapy in elderly patients can be based on pharmacokinetic data. Both healthy aging and comorbid disease can alter the responsiveness of the body to drugs and to their absorption, distribution and elimination. Altered absorption in the elderly has not been documented after oral ingestion of any anticonvulsant drug. Increased adipose tissue in the elderly may raise the apparent volume of distribution (Vd) of lipid-soluble drugs. An increased Vd in the elderly has been shown for diazepam and clobazam, but not midazolam. The data are inconclusive for phenytoin and valproic acid (sodium valproate). The decreased plasma protein binding that often occurs in the elderly has few clinical consequences. The reduced liver function that to occur with aging seems to affect the elimination of drugs that are mainly cleared by oxidative metabolism [e.g. carbamazepine, phenytoin and phenobarbital (phenobarbitone)]. Reduced clearances for methylphenobarbital (methylphenobarbitone), diazepam, midazolam and clobazam occur in elderly men, but not in women. The reduced renal function that is seen in old age affects the disposition of drugs that are eliminated mainly by direct renal excretion. Thus. the clearances of vigabatrin and gabapentin correlate with creatinine clearance. Such considerations may help guide anticonvulsant dosage in the elderly.
- Published
- 1997
- Full Text
- View/download PDF
21. Effects of pregnancy on various pathways of human antiepileptic drug metabolism.
- Author
-
Bernus I, Hooper WD, Dickinson RG, and Eadie MJ
- Subjects
- Adult, Anticonvulsants blood, Anticonvulsants therapeutic use, Carbamazepine blood, Carbamazepine metabolism, Carbamazepine therapeutic use, Female, Humans, Phenytoin blood, Phenytoin therapeutic use, Pregnancy Complications blood, Pregnancy Complications drug therapy, Anticonvulsants metabolism, Phenytoin metabolism, Pregnancy metabolism, Pregnancy Complications metabolism
- Abstract
Ratios of phenytoin and carbamazepine doses to steady-state plasma concentrations of the drugs (apparent clearances) increase in pregnant women. Mean phenytoin clearance to urinary unconjugated p-hydroxyphenytoin increased from 0.28 +/- SD 0.18 to 0.74 +/- SD 0.37 L/day in 13 pregnant women; mean clearance to p-hydroxyphenytoin glucuronide increased proportionately less (15.25 +/- SD 5.43 to 31.94 +/- SD 16.30 L/day), the proportion of the metabolite that was conjugated falling from 98.4 +/- SD 0.72% to 97.65 +/- SD 0.67%. Mean clearances to urinary phenytoin and phenytoin-dihydrodiol did not increase. In 10 epileptic women, mean clearances of carbamazepine to urinary (a) carbamazepine-10,11-epoxide (1.66 +/- SD 1.2 to 3.70 +/- SD 2.09 L/day), (b) unconjugated carbamazepine-10,11-trans-diol (33.93 +/- SD 10.21 to 47.01 +/- SD 19.58 L/day). (c) unconjugated carbamazepine-acridan (0.24 +/- SD 0.12 to 0.47 +/- SD 0.34 L/day), and (d) unconjugated 2-hydroxy-carbamazepine (0.08 +/- SD 0.09 to 0.66 +/- SD 1.14 L/day) all increased during pregnancy. Mean clearance to unconjugated 3-hydroxy-carbamazepine decreased (0.53 +/- SD 0.25 to 0.18 +/- SD 0.23 L/day). In contrast, mean clearances of carbamazepine to the glucuronides of its first stage metabolites (carbamazepine-diol, 2- and 3-hydroxy-carbamazepine and carbamazepine-acridan, respectively) did not increase in pregnancy. The conversion of carbamazepine to carbamazepine-epoxide increased proportionately more than the conversion of carbamazepine-epoxide to carbamazepine-diol. Pregnancy was thus associated with increased microsomal oxidations of phenytoin and carbamazepine, without proportionate increases in the subsequent hydrolysis of carbamazepine-10,11-epoxide and in the O-glucuronidations of the earlier stage metabolites.
- Published
- 1997
- Full Text
- View/download PDF
22. Dose-dependent metabolism of carbamazepine in humans.
- Author
-
Bernus I, Dickinson RG, Hooper WD, and Eadie MJ
- Subjects
- Adult, Aged, Anticonvulsants blood, Anticonvulsants therapeutic use, Carbamazepine analogs & derivatives, Carbamazepine blood, Carbamazepine therapeutic use, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Humans, Male, Metabolic Clearance Rate, Middle Aged, Regression Analysis, Anticonvulsants pharmacokinetics, Carbamazepine pharmacokinetics, Epilepsy drug therapy
- Abstract
48-h steady-state metabolic balance studies were carried out in 17 adults receiving long-term anticonvulsant monotherapy. With increasing carbamazepine dosage (1) carbamazepine overall plasma apparent clearance (CL/F), (2) plasma clearance of carbamazepine to urinary carbamazepine-10,11-epoxide, (3) plasma clearance of carbamazepine-10,11-epoxide to urinary unconjugated carbamazepine-10,11-trans-diol and (4) plasma clearances of carbamazepine to urinary 2- and 3-hydroxy carbamazepine all increased. However, with increasing carbamazepine dose there was no increase in the clearance of carbamazepine to (5) its acridan derivative in urine or of (6) the diol, phenolic or acridan metabolites to their metabolically subsequent conjugates excreted in urine. These findings are consistent with ongoing dose-dependent autoinduction of carbamazepine metabolism along the first two stages, but not the final stage, of the epoxide-diol pathway and, to a lesser extent, along pathways yielding phenolic metabolites. However, conjugations of the various plasma phase I metabolites of carbamazepine are not dose-dependent. Plasma concentration ratios of substances involved in consecutive stages of the epoxide-diol pathway, as in previous published studies, suggested apparent dose dependence of the epoxide-->unconjugated diol stage only. Presumably, increased flux along the first two stages of the full epoxide-diol pathway reduces plasma carbamazepine and carbamazepine-10,11-epoxide concentrations largely in parallel, concealing the dose dependence of the conversion of carbamazepine to its epoxide.
- Published
- 1996
- Full Text
- View/download PDF
23. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation.
- Author
-
Hooper WD, Franklin ME, Glue P, Banfield CR, Radwanski E, McLaughlin DB, McIntyre ME, Dickinson RG, and Eadie MJ
- Subjects
- Adult, Anticonvulsants pharmacology, Chromatography, High Pressure Liquid, Double-Blind Method, Drug Interactions, Felbamate, Humans, Male, Metabolic Clearance Rate, Oxidation-Reduction, Phenylcarbamates, Placebos, Propylene Glycols blood, Propylene Glycols pharmacology, Valproic Acid blood, Valproic Acid pharmacology, Anticonvulsants pharmacokinetics, Propylene Glycols pharmacokinetics, Valproic Acid metabolism
- Abstract
We assessed the effects of felbamate (FBM) on the disposition of valpr oic acid (VPA) in healthy volunteer men. Eighteen subjects received sodium VPA, 400 mg/day for 21 days. Plasma and urine samples were taken on day 7 to document the steady-state disposition of VPA alone. From day 8 to day 21, subjects received placebo or FBM at the following doses (mg/day): 1,200, 2,400, 3,000, or 3,600 (n = 2-4 per group). Many adverse events (AE) occurred from about day 10; 2 subjects dropped out and 1 continued on a reduced FBM dose. Pharmacokinetic studies were repeated on day 21 for the 16 subjects who completed the study. FBM was measured in plasma and urine by high-performance liquid chromatography (HPLC). VPA and its 2-en, 4-en, and 3-oxo metabolites in plasma, and VPA (nonconjugated and total), and its 3-oxo and 4-hydroxy metabolites in urine were measured by gas chromatography/mass spectrometry (GC/MS). Mean plasma FBM trough concentrations on day 21 ranged from 26.9 mu g/ml (1,200 mg dose) to 76.8 mu g/ml (3,600-mg dose). Mean plasma VPA C max values were 32-42 mu g/ml in the various subgroups when VPA only was administered. Higher plasma VPA levels were observed when FBM was administered concurrently (55.4-63.8 mu g/ml). The excretion of 3-oxo-VPA in urine was significantly lower on day 21 than on day 7, whereas VPA-glucuronide was significantly increased. The effects of FBM on VPA disposition were dose dependent and were maximal at approximately 2400 mg/day. FBM has caused significant inhibition of the beta-oxidation pathway for VPA metabolic clearance, and this had been largely compensated by increased VPA glucuronidation.
- Published
- 1996
- Full Text
- View/download PDF
24. Enantioselective analysis of sotalol in plasma by reversed-phase high-performance liquid chromatography using diastereomeric derivatives.
- Author
-
Hooper WD and Baker PV
- Subjects
- Adrenergic beta-Antagonists pharmacokinetics, Humans, Indicators and Reagents, Isocyanates, Naphthalenes, Reproducibility of Results, Sensitivity and Specificity, Sotalol pharmacokinetics, Spectrometry, Fluorescence, Stereoisomerism, Adrenergic beta-Antagonists blood, Chromatography, High Pressure Liquid methods, Sotalol blood
- Abstract
A procedure for the concurrent determination of the (+)- and (-)-enantiomers of sotalol in plasma using high-performance liquid chromatography of diastereomeric derivatives is described. Sotalol is extracted from a 0.5-ml aliquot of plasma at pH 9.3 using ethyl acetate. Atenolol is used as the internal standard. The ethyl acetate is removed under vacuum, and the residue derivatized with R-(-)-1-(1-naphthyl)ethyl isocyanate (NEIC, 0.005% in chloroform) in the presence of trace quantities of carbonate buffer. The chloroform is removed, the residue reconstituted in mobile phase (acetonitrile-water, 39:61, v/v), and an aliquot injected into the HPLC column. A C18 trapping column is used to retain excess derivatizing reagent. While the derivatives are separated on a C18 analytical column with the isocratic mobile phase mentioned above at 1.5 ml/min, the column-switching allows back-flushing of the trapping column to prepare for the next injection. The derivatives were detected using a fluorescence detector with excitation wavelength 280 nm and emission wavelength 320 nm. The method was fully validated, and shown to have excellent linearity, specificity, sensitivity, accuracy and precision. It has been applied to the determination of (+)- and (-)-sotalol in plasma from twelve subjects dosed with racemic sotalol.
- Published
- 1995
- Full Text
- View/download PDF
25. Metabolism of carbamazepine and co-administered anticonvulsants during pregnancy.
- Author
-
Bernus I, Hooper WD, Dickinson RG, and Eadie MJ
- Subjects
- Adult, Anticonvulsants therapeutic use, Carbamazepine pharmacokinetics, Carbamazepine urine, Drug Therapy, Combination, Epilepsy drug therapy, Female, Humans, Phenytoin metabolism, Phenytoin therapeutic use, Pregnancy, Anticonvulsants metabolism, Carbamazepine metabolism, Epilepsy metabolism, Pregnancy Complications metabolism
- Abstract
Urinary excretions of carbamazepine, carbamazepine-10,11-epoxide, carbamazepine-10,11-trans-diol, 9-hydroxyacridan and 2- and 3-hydroxycarbamazepine were measured at various stages of pregnancy, and in the post-natal period, in ten epileptic women, six of whom took no other enzyme-inducing anticonvulsant and four of whom took such co-medication. Mean plasma carbamazepine apparent clearance was increased in pregnancy, but only by virtue of the increased clearance in the anticonvulsant co-medicated women. Alterations in the proportions of the carbamazepine dose cleared via the various excretion pathways studied were quantitatively minor, but there was evidence consistent with impaired conversion of carbamazepine-10,11-epoxide to carbamazepine-10,11-trans-diol during all pregnancies studied. Clearances of carbamazepine to the various excretory products studied were consistent with there being (i) increased urinary excretion of unmetabolised drug in pregnancy, possibly related to the increased glomerular filtration rate, (ii) increased formation of oxidative metabolites of the drug, particularly in women co-medicated with enzyme-inducing anticonvulsants, this effect being offset, in full (in non-co-medicated women) or in part (in co-medicated women) by (iii) inhibition of the epoxide-diol pathway in pregnancy, an inhibition to which folate intake may have contributed.
- Published
- 1995
- Full Text
- View/download PDF
26. Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities.
- Author
-
Gillam EM, Guo Z, Ueng YF, Yamazaki H, Cock I, Reilly PE, Hooper WD, and Guengerich FP
- Subjects
- Amino Acid Sequence, Base Sequence, Catalysis, Cytochrome P-450 CYP3A, Cytochrome P-450 Enzyme System chemistry, Cytochrome P-450 Enzyme System metabolism, DNA Restriction Enzymes, Escherichia coli enzymology, Humans, Hydrogen-Ion Concentration, Mixed Function Oxygenases chemistry, Mixed Function Oxygenases metabolism, Molecular Sequence Data, Plasmids, Recombinant Proteins chemistry, Recombinant Proteins metabolism, Sequence Homology, Substrate Specificity, Cytochrome P-450 Enzyme System genetics, Escherichia coli genetics, Gene Expression
- Abstract
Cytochrome P450 (P450) 3A5 is a human enzyme with 85% amino acid sequence identity to the more predominantly expressed P450 3A4 and has been reported to have overlapping catalytic specificity. The 5'-terminus of a P450 3A5 cDNA was modified for optimal expression in Escherichia coli using the vector pCW, by aligning the MALLLAVFL N-terminal sequence of recombinant bovine P450 17A (H. J. Barnes, M. P. Arlotto, and M. R. Waterman, (1991) Proc. Natl. Acad. Sci. USA 88, 5597-5601) to the 3A5 cDNA. Two constructs were made, differing by their identity with the modified 3A4 N-terminal sequence (E. M. J. Gillam, T. Baba, B-R. Kim, S. Ohmori, and F. P. Guengerich, (1993) Arch. Biochem. Biophys. 305, 123-131). The first modified sequence (3A5#1) was identical to recombinant P450 3A4 up to codon 15, the 3A5 sequence being introduced thereafter. In the other (3A5#2), the successful 3A4 N-terminal nucleotide sequence was attached to codon 30. The yield was greater than fourfold higher in the first construct [up to 260 nmol (liter culture)-1]. The recombinant P450 3A5 (construct 1) was purified to electrophoretic homogeneity using a variation of a three-step procedure developed previously for P450 3A4, with an overall yield of approximately 40%. Purified P450 3A5 was active in nifedipine oxidation, testosterone 6 beta-hydroxylation, aflatoxin 3 alpha-hydroxylation and 8,9-epoxidation, ethylmorphine N-demethylation, erythromycin N-demethylation, and d-benzphetamine N-demethylation. The reconstitution of nifedipine oxidation, testosterone 6 beta-hydroxylation, and the aflatoxin oxidation activities showed dependence upon the presence of cytochrome b5, divalent cations, phospholipid mixtures, glutathione, and cholate similar to that previously found for purified P450 3A4. However, rates of the N-demethylations of ethylmorphine, erythromycin, and d-benzphetamine were as high or higher for P450 3A5 than P450 3A4 and were not particularly dependent upon modifications of reconstitution systems [corrected].
- Published
- 1995
- Full Text
- View/download PDF
27. Stereoselective hydroxylation of tacrine in rats and humans.
- Author
-
Hooper WD, Pool WF, Woolf TF, and Gal J
- Subjects
- Aged, Animals, Cholinesterase Inhibitors urine, Chromatography, High Pressure Liquid, Female, Glucuronates metabolism, Humans, Hydroxylation, Male, Microsomes, Liver metabolism, Middle Aged, Rats, Stereoisomerism, Tacrine analogs & derivatives, Tacrine urine, Tacrine pharmacokinetics
- Abstract
An enantiospecific method was developed for assessing the stereochemistry of tacrine (9-amino-1,2,3,4-tetrahydroacridine monohydrochloride monohydrate; THA) metabolism to 1-hydroxytacrine (1-OH-THA) in humans and rats. In addition, limited metabolic studies with human liver microsomal preparations were conducted, and the stereochemistry of rac-1-OH-THA disposition was also examined. The analytical method incorporates an achiral normal phase separation and isolation of 1-OH-THA, followed by a chromatographic step using chiral normal-phase chromatography to resolve the enantiomers of 1-OH-THA. The achiral method was applied to quantitation of total 1-OH-THA in human urine specimens collected for 24 hr following administration of a single 40 mg oral dose of tacrine to 15 healthy elderly volunteers. Total 1-OH-THA accounted for approximately 5% of the administered dose. THA and 2-OH-THA were also quantitated and found to comprise < 1% and approximately 2% of the administered dose, respectively. 4-OH-THA was not detectable. The dextrorotatory (+)-isomer comprised approximately 94% of the 1-OH-THA recovered in urine. In vitro studies utilizing human liver microsomes found enantioselective formation of the (+)-isomer (approximately 90%), whereas incubations with rac-1-OH-THA showed residual substrate to be racemic. The method was also applied to determination of the enantiomeric composition of 1-OH-THA in the urine of rats given a single oral 16 mg/kg dose of THA. The percentage of 1-OH-THA excreted in urine as the (+)-isomer was 94%.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1994
28. Urinary excretion of phenobarbitone and its metabolites in chronically treated patients.
- Author
-
Bernus I, Dickinson RG, Hooper WD, and Eadie MJ
- Subjects
- Adult, Aged, Aged, 80 and over, Biotransformation, Chromatography, High Pressure Liquid, Epilepsy drug therapy, Female, Humans, Male, Middle Aged, Phenobarbital analogs & derivatives, Phenobarbital pharmacokinetics, Phenobarbital therapeutic use, Epilepsy urine, Phenobarbital urine
- Abstract
The elimination of phenobarbitone (PB) was studied in 14 chronically treated epileptic patients under steady state conditions. PB, [S]-PB-N-glucoside ([S]-PB-N-G) and p-hydroxy-PB (p-OH-PB) were assayed in urine by a HPLC method. Some 57% of the daily dose was recovered in urine, 14% as [S]-PB-N-G, 16% as p-OH-PB (conjugated plus non-conjugated) and 27% as unaltered PB. Thus PB-N-G formation contributed significantly to the elimination of PB during long-term administration of the drug, and there was reason to suspect that some of the PB-N-G formed may have already been degraded to untraced products before excretion from the body.
- Published
- 1994
- Full Text
- View/download PDF
29. Early stage autoinduction of carbamazepine metabolism in humans.
- Author
-
Bernus I, Dickinson RG, Hooper WD, and Eadie MJ
- Subjects
- Acridines metabolism, Adult, Carbamazepine analogs & derivatives, Carbamazepine blood, Carbamazepine pharmacokinetics, Carbamazepine urine, Confidence Intervals, Humans, Male, Oxidation-Reduction, Carbamazepine metabolism
- Abstract
Six healthy young adult male volunteers were given two 600 mg (2540 mu moles) oral doses of carbamazepine (CBZ) 5 days apart. Serial concentrations of CBZ and its 10,11-epoxy (CBZ-epoxide) and 10,11-dihydro-10,11-trans-dihydroxy (CBZ-diol) metabolites in plasma, and daily excretions of these substances and the 2-hydroxy (2-OH-CBZ), 3-hydroxy (3-OH-CBZ) and 9-hydroxymethyl-10-carbamoylacridan (acridan) metabolites in urine were followed for 5 days after each dose. Pharmacokinetic analysis showed that autoinduction of CBZ metabolism was present within 6-10 days of the initial drug dose. The mean oral clearance of CBZ increased from 1.48 to 1.74 l.h-1 (difference 0.26 l.h-1, 95% confidence interval 0.11 to 0.41 l.h-1) and the mean percentage urinary recovery of the amount of CBZ eliminated increased from 41.8% to 44.6% (difference 2.8%, 95% confidence interval 0.5 to 5%) between the two studies 5 days apart. The data for daily clearance to metabolite and the time-courses of the plasma CBZ-epoxide to CBZ and CBZ-diol to CBZ concentration ratios suggested that autoinduction had begun by the second day after CBZ intake, and involved not only the epoxide-diol pathway but, to a lesser extent, the oxidations to phenolic derivatives.
- Published
- 1994
- Full Text
- View/download PDF
30. Are enantioselective assay methods necessary for comparative bioavailability studies on racemic drugs?
- Author
-
Hooper WD
- Subjects
- Animals, Humans, Biological Availability, Pharmacokinetics, Stereoisomerism
- Published
- 1993
31. Enantioselective versus non-enantioselective assays in comparative bioavailability studies with racemic drugs.
- Author
-
Hooper WD, Dickinson RG, and Gal J
- Subjects
- Biological Availability, Drug Evaluation, Pharmacokinetics, Stereoisomerism
- Published
- 1992
- Full Text
- View/download PDF
32. Urinary metabolites of phenobarbitone, primidone, and their N-methyl and N-ethyl derivatives in humans.
- Author
-
Treston AM and Hooper WD
- Subjects
- Adult, Alkylation, Humans, Hydroxylation, Male, Phenobarbital analogs & derivatives, Phenobarbital urine, Primidone analogs & derivatives, Primidone urine, Prospective Studies, Phenobarbital metabolism, Primidone metabolism
- Abstract
1. Phenobarbitone (1) and three of its N-alkyl derivatives, and primidone (10) and four of its N-alkyl derivatives, were orally administered separately to two human volunteers. Total urine was collected for approximately 2 weeks following each dose, and the drugs and their metabolites were assayed by g.l.c.-mass spectrometry. 2. Recoveries in the phenobarbitone series increased from approximately 40% to approximately 50% as alkylation of (1) increased. There was a linear relationship between the extent of p-hydroxylation and the lipophilicity (log P) of the substrates. The increased total recovery was largely attributable to increased p-hydroxylation. 3. Urinary recoveries in the primidone series decreased from approximately 80% for (10) to approximately 30% for its diakyl derivatives, despite a slight increase in p-hydroxylation with increasing alkylation (and increasing lipophilicity). The decreased recovery was mainly the result of decreased urinary excretion of the drug.
- Published
- 1992
- Full Text
- View/download PDF
33. Comparative metabolism of clinically important precursors of N-desmethyldiazepam using phenobarbitone-pretreated rat liver microsomes.
- Author
-
Hooper WD, Bruce I, and Reilly PE
- Subjects
- Animals, Benzodiazepinones metabolism, Diazepam metabolism, Hydroxylation, Male, Methylation, Microsomes, Liver metabolism, Prazepam metabolism, Rats, Rats, Inbred Strains, Structure-Activity Relationship, Anti-Anxiety Agents, Benzodiazepines, Microsomes, Liver drug effects, Nordazepam metabolism, Phenobarbital pharmacology
- Abstract
Phenobarbitone-pretreated male Sprague-Dawley rat liver microsomes were used to examine C3-hydroxylation and N-dealkylation of four clinically important benzodiazepines: diazepam (DZP), prazepam (PZP), pinazepam (PIN) and halazepam (HZP). These substrates differ only in the nature of the N-substituent of the B ring and N-desmethyldiazepam (DMD) is the N-dealkylation product in each case. C3-Hydroxylation was accordingly also studied with DMD as substrate. All monooxygenations were studied with substrates at a concentration of 10 microM, in the absence of solubilizing agents, and under conditions where the production of secondary metabolites was minimized. A 20-fold variation in the rate of C3-hydroxylation was recorded across the five substrates with HZP showing the highest rate and DMD showing the lowest rate. An almost equally large range of variation was shown for the N-dealkylation reaction, with PZP undergoing this biotransformation more than 17 times faster than DZP. Log P values (a measure of lipophilicity) for the five substrates were determined using an HPLC method and a remarkable lack of correspondence between this substrate parameter and either of the monooxygenations was noted. This suggests that multiple substrate determinants govern the relative rates of these monooxygenations. It was, however, notable that the additive rate of metabolism of these substrates by both monooxygenase routes did show an excellent correlation with substrate lipophilicity.
- Published
- 1992
- Full Text
- View/download PDF
34. Enantioselective pharmacokinetics of ethotoin in humans following single oral doses of the racemate.
- Author
-
Hooper WD, O'Shea NJ, and Qing MS
- Subjects
- Administration, Oral, Adult, Female, Humans, Hydantoins administration & dosage, Male, Middle Aged, Stereoisomerism, Hydantoins pharmacokinetics
- Abstract
Racemic ethotoin (1000 mg) was administered orally as a single dose to six healthy adult volunteers. Blood samples were collected at appropriate times for 120 h following the dose. Ethotoin was quantified enantio-selectively in plasma using a novel chiral column HPLC procedure. One of the enantiomers of the chiral metabolite, 5-phenylhydantoin, was also quantified in the HPLC method. The Cmax and AUC0-infinity values for (+)-(S)-ethotoin were significantly greater than those for (-)-(R)-ethotoin (ratio of mean AUC0-infinity values 0.88), but the elimination half-lives of the isomers were virtually identical [12.35 +/- 5.15 h for (-)-(R)-ethotoin; 12.28 +/- 5.34 h for (+)-(S)-ethotoin]. Parameters derived from AUC0-infinity (Cl0/F and V(area)/F) also differed slightly between the isomers. The data were interpreted as indicating a small difference in the absorption of the two isomers; it seemed unlikely, in terms of the identical elimination rates, that their metabolic profiles would differ greatly. The 5-phenylhydantoin was eliminated with a significantly longer half-life (18.69 +/- 6.11 h) than that of ethotoin. Enantioselectivity in the pharmacokinetics of ethotoin is therefore a minor issue.
- Published
- 1992
- Full Text
- View/download PDF
35. Metabolism of diazepam and related benzodiazepines by human liver microsomes.
- Author
-
Hooper WD, Watt JA, McKinnon GE, and Reilly PE
- Subjects
- Adult, Aged, Chromatography, High Pressure Liquid, Ethylmorphine-N-Demethylase antagonists & inhibitors, Ethylmorphine-N-Demethylase metabolism, Female, Humans, In Vitro Techniques, Male, Middle Aged, Substrate Specificity, Benzodiazepines metabolism, Diazepam metabolism, Microsomes, Liver metabolism
- Abstract
The metabolism of diazepam has been studied in vitro using microsomal preparations from five human livers. An HPLC method was developed for the assay of diazepam, its congeners and its metabolites. Various methods for the incorporation of diazepam into the incubation medium were explored. It was shown that the use of organic solvents or small quantities of hydrochloric acid enhanced the solubility of this substrate. However all of the organic solvents tested were associated with substantial (around 50%) inhibition of metabolism of diazepam by both major pathways (N-demethylation and C3-hydroxylation). The use of hydrochloric acid gave satisfactory solubilization of diazepam, but not of pinazepam, prazepam or halazepam. Detailed metabolic studies were conducted only for diazepam, using neither hydrochloric acid nor organic solvents in the incubation medium. Formation of N-desmethyl-diazepam increased approximately linearly with diazepam concentration to 200 microM, and did not show saturation. Formation of temazepam gave a curved profile over the same range of diazepam concentrations, suggestive of a sigmoidal relationship. Michaelis-Menten parameters could not be determined for either reaction, but intrinsic clearances for N-demethylation varied over a 6-fold range. Diazepam N-demethylation was apparently promoted by the inclusion of temazepam in the incubation medium, while C3-hydroxylation of diazepam was enhanced in the presence of N-desmethyldiazepam. Mephenytoin in the incubation mixture had no effect on diazepam metabolism by either pathway. The present studies have defined some of the methodological problems inherent in in vitro metabolic studies with benzodiazepines, and have shed further light on the metabolism of diazepam in vitro by human liver.
- Published
- 1992
- Full Text
- View/download PDF
36. Phenytoin metabolism during pregnancy.
- Author
-
Eadie MJ, McKinnon GE, Dickinson RG, Hooper WD, and Lander CM
- Subjects
- Epilepsy blood, Female, Humans, Phenytoin blood, Pregnancy, Pregnancy Complications blood, Time Factors, Epilepsy urine, Phenytoin analogs & derivatives, Phenytoin urine, Pregnancy Complications urine
- Abstract
The steady-state 72 h urinary excretion of various phenytoin metabolites has been measured in 10 epileptic women, whose plasma phenytoin concentrations relative to the phenytoin dose fell during pregnancy and rose again post-partum. In later pregnancy and post partum, a mean of 61.3% and 48.9%, respectively, of the total daily phenytoin dose was eliminated as 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). Even though p-HPPH accounts for not much more than half the total daily phenytoin dose, increased excretion of this metabolite sufficed to account for the elimination of the entire increase in the dose of phenytoin required during pregnancy. There was no definite increase in the excretion of any other (minor) metabolite measured. Thus pregnancy seems not to enhance uniformly the capacity of the various metabolic pathways of phenytoin.
- Published
- 1992
- Full Text
- View/download PDF
37. Single oral dose pharmacokinetics and comparative bioavailability of danazol in humans.
- Author
-
Hooper WD, Eadie MJ, and Dickinson RG
- Subjects
- Administration, Oral, Adolescent, Adult, Biological Availability, Chemistry, Pharmaceutical, Danazol blood, Humans, Male, Danazol pharmacokinetics
- Abstract
A comparative bioavailability study was conducted with two capsule formulations of danazol (200 mg) in 16 healthy adult male volunteers. Fasting subjects received single doses (400 mg) of each formulation on separate occasions 1 week apart. Blood samples were drawn at specified times up to 32 h after the dose and danazol concentrations in plasma were determined by a specific and sensitive HPLC method. The results for one subject were excluded as outlier values. The data from the other 15 subjects showed small differences, which did not achieve statistical significance between the formulations with respect to Cmax, Tpeak and AUC0-infinity. The mean elimination half-life for danazol was 9.44 +/- SD 2.74 h and the mean apparent total body clearance was 710 +/- SD 2161 h-1. These data differed from previously published results, probably as a result of the more sensitive and specific assay method used in the present work. It is likely that a high proportion of the oral dose of danazol is eliminated by presystemic metabolism.
- Published
- 1991
- Full Text
- View/download PDF
38. Effects of ethinylestradiol and testosterone implants on hepatic microsomal cytochrome P450 monooxygenases of birth gonadectomized male and female Dark Agouti rats.
- Author
-
Reilly PE, Mason SR, and Hooper WD
- Subjects
- Animals, Drug Implants, Enzyme Induction, Ethinyl Estradiol administration & dosage, Female, Kinetics, Male, Microsomes, Liver drug effects, Rats, Rats, Inbred Strains, Testosterone administration & dosage, Cytochrome P-450 Enzyme System biosynthesis, Ethinyl Estradiol pharmacology, Isoenzymes biosynthesis, Microsomes, Liver enzymology, Orchiectomy, Ovariectomy, Testosterone pharmacology
- Abstract
Monooxygenases in the cytochrome P450 IIIA subfamily are induced by a number of their xenobiotic substrates and by testosterone, an endobiotic substrate of importance in their regulation. 17 alpha-Ethinylestradiol (EE) is also metabolized by these enzymes and in this study Dark Agouti rats were used to examine the effects of subcutaneous implantation of controlled release silastic capsules containing EE to determine if this steroid also induces these enzymes. Data were compared with results obtained from equivalent groups of animals implanted with capsules containing testosterone propionate (TP). Liver microsomes prepared from male and female rats were used to identify intrinsic gender differences in the monooxygenases studied and gender differences in the responses to the implanted steroids were also determined. Effects due to imprinting of growth hormone secretion patterns were controlled by using male and female birth gonadectomized animals. Results obtained from groups with blank implants showed there were no effects due to the silastic implant material itself on the monooxygenases studied. The specific activities of erythromycin N-demethylation in liver microsomes of both EE and TP implanted male and female birth gonadectomized animals were enhanced relative to corresponding blank implanted controls consistent with both steroids having an effect to induce activity attributable to cytochrome P450 IIIA isoforms. Immunoinhibition studies using microsomes from EE treated female rats with erythromycin as substrate provided further evidence for this steroid having this induction effect. The specific activity of ethylmorphine N-demethylation was however not increased in microsomes prepared from the EE implanted female animals and was decreased in the corresponding male preparations. These findings distinguished the response to this steroid from that to TP and suggested induction by this estrogen of an isoform(s) having a more limited range of substrates than has characteristically been found in this subfamily. EE treatment also caused an increase in diazepam C3 hydroxylase consistent with an effect to induce P450 IIIA activity but this was found only in microsomes from birth gonadectomized female animals. This was in contrast to the effect of TP treatment which produced increases in this monooxygenase in both male and female animals. Another gender specific effect of EE was a striking decrease in morphine N-demethylase activity seen only in birth gonadectomized male rats. This again contrasted with the effect of TP which caused a marked increase in this activity in liver microsomes of both male and female birth gonadectomized animals consistent with the proposal that testosterone is important in the regulation of this activity.(ABSTRACT TRUNCATED AT 400 WORDS)
- Published
- 1991
- Full Text
- View/download PDF
39. Facile hydrolysis of mebeverine in vitro and in vivo: negligible circulating concentrations of the drug after oral administration.
- Author
-
Dickinson RG, Baker PV, Franklin ME, and Hooper WD
- Subjects
- Adult, Animals, Chromatography, High Pressure Liquid, Half-Life, Humans, Hydrolysis, In Vitro Techniques, Male, Parasympatholytics analysis, Parasympatholytics pharmacokinetics, Phenethylamines analysis, Phenethylamines pharmacokinetics, Physostigmine pharmacology, Rats, Rats, Inbred Strains, Tissue Distribution, Vanillic Acid analogs & derivatives, Vanillic Acid metabolism, Vanillic Acid pharmacokinetics, Parasympatholytics metabolism, Phenethylamines metabolism
- Abstract
The HPLC methods for the determination of plasma concentrations of the antispasmodic agent mebeverine (0.01-10 micrograms/mL) and its hydrolysis product veratric acid (0.1-50 micrograms/mL) are presented. Mebeverine was demonstrated to hydrolyze readily in fresh unbuffered human and rat plasma samples ex vivo. Hydrolysis in human plasma was completely inhibited in the presence of the esterase inhibitor physostigmine sulfate, at a concentration of 130 micrograms/mL. However, the inhibitor was only partially effective in blocking mebeverine hydrolysis in rat plasma. After oral administration of mebeverine.HCl (270 mg) to fasted human volunteers, measurable concentrations of the drug were not found in plasma. By contrast, the metabolite veratric acid achieved considerable concentrations (mean peak plasma concentration of 13.5 micrograms/mL at 40-80 min). After iv administration of mebeverine.HCl (2 mg) to rats, the drug was rapidly eliminated from plasma (mean half-life of 29 min) with simultaneous appearance of veratric acid (mean peak plasma concentration of 1.80 micrograms/mL at 15-30 min). However, after oral administration of the same dose, only traces of mebeverine were found in plasma, with the exception of one rat. Veratric acid again achieved considerable concentrations (mean peak plasma concentration of 0.90 micrograms/mL at 15 min-4 h). The results show that mebeverine undergoes rapid and extensive first-pass metabolism involving hydrolysis of the ester function, and that negligible circulating concentrations of the parent drug are found in humans.
- Published
- 1991
- Full Text
- View/download PDF
40. The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans.
- Author
-
Hooper WD and Qing MS
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Sex Factors, Stereoisomerism, Mephobarbital pharmacokinetics
- Abstract
In this clinical investigation, four groups of subjects (eight young women and eight young men [age range, 18 to 25 years], and eight elderly women and eight elderly men [greater than 60 years of age]) received single oral doses (400 mg) of racemic mephobarbital. The apparent total body clearance of R-mephobarbital was much greater and the elimination half-life was much shorter in the young men compared with the other three groups. This enantiomer displayed an age-dependent gender effect and a gender-dependent age effect in its metabolism. The apparent total body clearance of the S-enantiomer was much lower than that of the R-enantiomer in all subjects and did not differ between subject groups, although the elimination half-life was slightly but significantly shorter in young males. A consequence of these enantiomeric differences was an apparently enhanced stereoselectivity in the metabolism of mephobarbital in young men. These substantial influences of age and gender on the stereoselective disposition of mephobarbital are consistent with recent findings concerning the expression and regulation of cytochrome P450 enzymes.
- Published
- 1990
- Full Text
- View/download PDF
41. Effect of food on absorption of lomefloxacin.
- Author
-
Hooper WD, Dickinson RG, and Eadie MJ
- Subjects
- 4-Quinolones, Absorption, Adult, Anti-Infective Agents blood, Anti-Infective Agents urine, Chromatography, High Pressure Liquid, Female, Humans, Male, Time Factors, Anti-Infective Agents pharmacokinetics, Anti-Infective Agents pharmacology, Fluoroquinolones, Food, Quinolones
- Abstract
Twelve subjects participated in an open-label, single-dose, balanced three-way crossover study in which the absorptions of lomefloxacin were compared following (i) an overnight fast, (ii) a carbohydrate meal, and (iii) a high-fat meal. The time to peak concentration of lomefloxacin was delayed, but peak concentration in plasma and amount of drug absorbed were unchanged following both meals.
- Published
- 1990
- Full Text
- View/download PDF
42. Determination of gabapentin in plasma and urine by capillary column gas chromatography.
- Author
-
Hooper WD, Kavanagh MC, and Dickinson RG
- Subjects
- Acetates blood, Acetates urine, Gabapentin, Humans, Acetates analysis, Amines, Chromatography, Gas methods, Cyclohexanecarboxylic Acids, gamma-Aminobutyric Acid
- Published
- 1990
- Full Text
- View/download PDF
43. Cytochrome P450IIIA enzymes in rat liver microsomes: involvement in C3-hydroxylation of diazepam and nordazepam but not N-dealkylation of diazepam and temazepam.
- Author
-
Reilly PE, Thompson DA, Mason SR, and Hooper WD
- Subjects
- Animals, Female, Hydroxylation, Kinetics, Male, Microsomes, Liver drug effects, Phenobarbital pharmacology, Rats, Rats, Inbred Strains, Sex Factors, Species Specificity, Substrate Specificity, Anti-Anxiety Agents metabolism, Cytochrome P-450 Enzyme System metabolism, Diazepam analogs & derivatives, Diazepam metabolism, Microsomes, Liver enzymology, Nordazepam metabolism, Oxidoreductases, N-Demethylating metabolism, Temazepam metabolism
- Abstract
Microsomes prepared from livers of male and female rats of nine inbred and outbred strains and of male Sprague-Dawley rats pretreated with monooxygenase-inducing agents were used to study N-dealkylation of diazepam and temazepam and C3-hydroxylation of diazepam and nordazepam. Both C3-hydroxylation reactions were more rapid in male than in female liver preparations, but this gender-dependent pattern was not seen with the N-dealkylation reactions. These results indicate the lack of identity of the monooxygenases responsible for the two kinds of reaction and suggest that male-specific enzyme(s) are responsible for the C3-hydroxylations. Induction studies were undertaken to further define these enzymes. To do this, liver microsomes prepared from male Sprague-Dawley rats pretreated with a variety of agents known to have different monooxygenase induction effects were used. With triacetyloleandomycin, dexamethasone, and phenobarbital pretreatment, the specific activities of the C3-hydroxylation reactions were selectively elevated over corresponding control values. These particular xenobiotics are known to enhance the abundance of cytochrome P450IIIA family enzymes, and our results strongly suggest the involvement of these enzymes in the benzodiazepine B ring monooxygenations. Formation of temazepam was also shown to be inhibited by triacetyloleandomycin. This effect was demonstrated to be equal in both saline-treated and dexamethasone-treated male Sprague-Dawley rat liver microsomes, with the antibiotic present either with diazepam throughout the entire incubation period or initially with NADPH in a preincubation mix for 15 min, following which C3-hydroxylation was initiated by the addition of diazepam. These results confirm the uniformity of the involvement of cytochrome P450IIIA family enzymes in diazepam C3-hydroxylation in untreated and inducer-treated rat liver microsomes. Recent studies with human and rabbit liver microsomal preparations have shown that orthologues of these enzymes also catalyze an equivalent hydroxylation in the B ring of midazolam. These findings, considered with the present results showing that the adjacent methyl N-substituent (absent in nordazepam but present in diazepam) did not affect the selectivity of these enzymes for the C3-hydroxylation reaction, suggest that neither steric nor electronic factors markedly influence catalysis of this monooxygenation by these enzymes.
- Published
- 1990
44. Metabolic studies with phenobarbitone, primidone and their N-alkyl derivatives: quantification of substrates and metabolites using chemical ionization gas chromatography-mass spectrometry.
- Author
-
Treston AM and Hooper WD
- Subjects
- Administration, Oral, Humans, Male, Phenobarbital administration & dosage, Phenobarbital metabolism, Primidone administration & dosage, Primidone metabolism, Gas Chromatography-Mass Spectrometry methods, Phenobarbital urine, Primidone urine
- Abstract
Metabolic studies with phenobarbitone, primidone and some of their N-alkyl derivatives required the concurrent assay of any mixture of these substrates (twelve compounds) and their major metabolites (an additional twenty-two compounds) in urine. The method described in the present report met this requirement by incorporating two complementary derivatization techniques into a gas chromatographic-mass spectrometric (GC-MS) assay procedure. Following hydrolysis of conjugates with beta-glucuronidase, urine samples were extracted with ethyl acetate (3 X 5 ml). The combined extracts were dried over sodium sulphate, divided into two equal portions, and the solvent was removed. One residue was derivatized by propylation using 1-iodopropane with base catalysis. The other residue was silylated using methyl-N-(tert.-butyldimethylsilyl)trifluoroacetamide. The derivatives in each case were analysed by GC-MS, using temperature-programmed packed-column GC and chemical ionization MS. Mass spectra were acquired over an appropriate mass range, and peak areas for the compounds of interest were determined from specific mass chromatograms. Satisfactory precision, accuracy, specificity and sensitivity were obtained for all analytes. All compounds produced satisfactory derivatives by at least one procedure; twelve compounds could be analysed by both techniques. The method illustrates the utility of chemical ionization GC-MS for the simultaneous quantitative analysis of multiple related analytes in complex biological samples.
- Published
- 1990
- Full Text
- View/download PDF
45. Enantioselective binding of mephobarbital to plasma proteins.
- Author
-
O'Shea NJ and Hooper WD
- Subjects
- Adult, Aging blood, Chromatography, High Pressure Liquid, Humans, Kinetics, Male, Middle Aged, Protein Binding, Stereoisomerism, Structure-Activity Relationship, Blood Proteins metabolism, Mephobarbital blood, Serum Albumin metabolism
- Abstract
The enantioselective protein binding of mephobarbital (MPB) was investigated in human plasma and human serum albumin solutions by equilibrium dialysis. A small but statistically significant difference was observed in the in vitro plasma protein binding of the enantiomers; (S)-MPB was approximately 59% bound and (R)-MPB approximately 67% bound. The binding to albumin [(S)-MPB: approximately 29% bound, and (R)-MPB: approximately 41% bound] was less than to plasma proteins but showed somewhat greater enantioselectivity, suggesting that albumin binding is a major source of the enantioselectivity in plasma. The effects of MPB concentration, of varying enantiomeric concentration ratio, and of phenobarbital on the enantioselective binding of MPB were studied. The effect of age was also investigated by measuring the binding in plasma from 8 young (18-25 yr) and 8 elderly (greater than 60 yr) male subjects who took single doses of MPB. The results were in close agreement with the in vitro binding data, and the binding of both enantiomers was marginally but significantly lower in the young compared with the elderly subjects. These differences in binding were consistent with previously observed pharmacokinetic differences between the two subject groups.
- Published
- 1990
- Full Text
- View/download PDF
46. Single-dose pharmacokinetics of metoclopramide.
- Author
-
Ross-Lee LM, Eadie MJ, Hooper WD, and Bochner F
- Subjects
- Administration, Oral, Adult, Biological Availability, Chemical Phenomena, Chemistry, Female, Humans, Injections, Intravenous, Kinetics, Male, Metoclopramide administration & dosage, Metoclopramide blood
- Abstract
The time courses of plasma metoclopramide concentrations were followed in six subjects after oral and intravenous single dose administration. Plasma concentration-time data following i. v. administration in each subject were found to fit a two compartment model with a mean terminal half-life of 4.55 h +/- 0.80 h and a mean distribution half-time of 0.35 h +/- 0.09 h. Volumes of distribution were high (3.43 +/- 1.181 . kg-1), and clearances (0.53 +/- 0.191 . kg-1 h-1) approached liver plasma flow. This suggests that metoclopramide occurs at higher concentrations in tissues than in plasma, and that its clearance is probably limited by liver blood flow rather than liver metabolic capacity. The postabsorption decline in metoclopramide plasma levels after oral administration was also biexponential in each subject. The terminal half-life was 5.17 h +/- 0.98 h. Mean volume of distribution and mean clearance were similar to intravenous values (after adjustment for bioavailability). Oral absorption was rapid with peak plasma concentrations being reached at a mean time of 0.93 h. A mean bioavailability of 0.77 was calculated for the six subjects, and it was postulated that this incomplete availability is due to a first-pass effect. The inter-individual variation in the degree of "first-pass' was considerable (0.47--1.14).
- Published
- 1981
- Full Text
- View/download PDF
47. Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.
- Author
-
Smith MT, Livingstone I, Eadie MJ, Hooper WD, and Triggs EJ
- Subjects
- Adult, Blood Pressure drug effects, Drug Evaluation, Female, Humans, Hypertension drug therapy, Kinetics, Middle Aged, Pregnancy, Pregnancy Complications drug therapy, Propranolol therapeutic use, Hypertension metabolism, Pregnancy Complications metabolism, Propranolol metabolism
- Abstract
The pharmacokinetics of propranolol (P) and its major metabolites, propranolol glucuronide (PGLUC), 4-hydroxypropranolol (4OHP), 4-hydroxypropranolol glucuronide (4OHPGLUC) and naphthoxylactic acid (NLA), (Walle et al. 1972) were determined, whenever possible, in the first, second and third trimesters of pregnancy in thirteen patients and also when these patients were at least three months post-partum. No correlations were found between the mean arterial blood pressure (post-therapy) or the fall in blood pressure as a result of the P therapy (p much greater than 0.05) and P dose, peak P plasma concentrations, peak 4-hydroxypropranolol (4OHP) plasma concentrations or peak (P plus 4OHP) plasma concentrations. However, a positive nonlinear relationship was found between the daily P dose (independent variable) and peak P plasma concentrations over the daily dose range 30-160 mg/day. The elimination half-lives of NLA for patients in the third trimester of pregnancy were significantly shorter (p = 0.072, df = 13) than those when the patients were at least three months post-partum. Also, the areas under the plasma level-time curves of NLA were significantly less (p less than 0.05, df = 13) for patients in the third trimester of pregnancy than when these patients were at least three months post-partum. The results of this study indicate that the pharmacokinetics of P, PGLUC, 4OHP and 4OHPGLUC are not significantly altered by pregnancy. However, the kinetics of NLA do appear to be altered. The formation of NLA by N-dealkylation of P and further oxidation, appears to be competitively inhibited by unidentified substances, perhaps endogenous steroids, especially in the third trimester when compared to at least three months post-partum.
- Published
- 1983
- Full Text
- View/download PDF
48. Plasma protein binding of carbamazepine.
- Author
-
Hooper WD, Dubetz DK, Bochner F, Cotter LM, Smith GA, Eadie MJ, and Tyrer JH
- Subjects
- Adolescent, Adult, Aged, Erythrocytes metabolism, Female, Humans, Kidney Diseases metabolism, Liver Diseases metabolism, Male, Middle Aged, Protein Binding drug effects, Temperature, Blood Proteins metabolism, Carbamazepine metabolism
- Abstract
The binding of carbamazepine to the proteins of human plasma has been studied using ultrafiltration techniques. In vitro studies at 37 degrees C showed the relation between concentration of unbound drug and total drug to be linear through the range of total concentration of 5 to 50 mug/ml. The per cent unbound drug increased slightly as concentration increased. There was little difference between the extent of binding at 4 degrees C and 20 degrees C, but more carbamazepine was unbound at 37 degrees C. Under in vitro conditions, 6 other anticonvulsants, and aspirin, were tested individually, each at high therapeutic or toxic concentration, and shown not to displace carbamazepine from plasma proteins to a significant degree. The extent of binding of carbamazepine in vivo was determined in a total of 54 plasma samples collected from treated patients; 26.9 plus or minus SD 9.4 percent of the drug was unbound. In blood samples from 23 of these patients, the red cell concentration of carbamazepine averaged 38.3 plus or minus SD 17.9 percent of the plasma concentration. The effects of hepatic and renal diseases on the carbamazepine binding capacity of plasma proteins were assessed by comparing the binding capacity of plasma from disease persons with that from normal subjects. There was no significant difference in binding capacity between plasma from patients with renal disease and that from normal subjects. However, the plasma from patients with hepatic disease bound a slightly lower percentage of carbamazepine than did normal plasma (p smaller than 0.05). This alteration did not correlate with changes in any of 15 biochemical parameters measured in these patients. The clinical significance of these results is discussed.
- Published
- 1975
- Full Text
- View/download PDF
49. Intermittent carbamazepine intoxication possibly related to altered absorption characteristics of the drug.
- Author
-
Eadie MJ and Hooper WD
- Subjects
- Absorption, Carbamazepine administration & dosage, Carbamazepine blood, Dizziness chemically induced, Drug Administration Schedule, Humans, Kinetics, Postural Balance drug effects, Vision Disorders chemically induced, Carbamazepine adverse effects
- Abstract
In Australia intermittent carbamazepine intoxication that occurs around the expected time of the peak post-dose plasma drug concentrations has been seen more frequently in recent years than in the past. Reworking of pharmacokinetic data from earlier studies of the drug suggests that, between 1977 and 1980, there was a change in the absorption profile of carbamazepine in the most widely used oral Australian preparation of the drug. The drug's absorption rate increased and its peak plasma levels occurred earlier. The reason for this altered absorption profile cannot now be traced, but it seems a possible explanation for the clinical problem that has emerged subsequently in a number of patients.
- Published
- 1987
- Full Text
- View/download PDF
50. Buccal absorption of ergotamine.
- Author
-
Sutherland JM, Hooper WD, Eadie MJ, and Tyrer JH
- Subjects
- Absorption, Administration, Oral, Adolescent, Adult, Caffeine administration & dosage, Drug Combinations, Ergotamine administration & dosage, Female, Humans, Hydrogen-Ion Concentration, Male, Time Factors, Caffeine metabolism, Ergotamine metabolism, Mouth Mucosa metabolism, Saliva metabolism
- Abstract
The rate of disappearance of ergotamine from the mouth after buccal administration has been studied in seven subjects. Allowance has been made for non-absorptive losses of the drug due to experimental technique. The absorption of ergotamine across the buccal mucosa appears to be a passive process, pH-dependent but independent of ergotamine concentration or the simultaneous presence of caffeine. Because of the low solubility of ergotamine at the pH of saliva, it is unlikely that therapeutically useful amounts of the drug would have absorbed across the buccal mucosa even after the drug had been in the mouth for five minutes.
- Published
- 1974
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.